To compare the efficacy and safety of mirabegron and vibegron in female patients with overactive bladder (OAB).
This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A meta-analysis of randomized controlled trials (RCTs) referred to the use of mirabegron and vibegron in female patients with OAB from PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed.
Three RCTs involving 371 patients were included. We found that vibegron was more effective in relieving urgency urinary incontinence in females with OAB compared to mirabegron [mean difference (MD)=0.25, 95% confidence interval (CI) 0.04 to 0.47, p=0.02]. And vibegron was similar to mirabegron in OAB symptom score (OABSS) [MD=0.22, 95% CI -0.32 to 0.76, p=0.42], urgency (MD=0.15, 95% CI -0.08 to 0.38, p=0.20), quality of life (QOL) (MD=-0.18, 95% CI -0.49 to 0.13, p=0.26), mean volume voided per micturition (MD=-6.16, 95% CI -21.50 to -9.17, p=0.43). In terms of the safety outcomes, there were no significant differences between mirabegron and control groups in terms of the total adverse events (TAEs) [odds ratio (OR)=0.75; 95% CI: 0.44 to 1.26; p=0.28], dry mouth (OR=1.01; 95% CI: 0.36 to 2.81; p=0.99), constipation (OR=0.69; 95% CI: 0.33 to 1.44; p=0.32), elevated post-void residual (PVR) (OR=0.35; 95% CI: 0.05 to 2.23; p=0.26), and dizziness (OR=1.02; 95% CI: 0.14 to 7.31; p=0.98).
In female OAB patients, the efficacy and safety of mirabegron and vibegron were similar. Vibegron may be more effective than mirabegron in relieving urgency urinary incontinence.
Urology. 2025 Feb 17 [Epub ahead of print]
Pu Liang, Liqian Yu, Bowen Xia, Dongxu Zhang
Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Beijing Institute of Infectious Diseases, Beijing, China; National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China., Qingdao university medical college, Qingdao, China., Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Institute of Urology, Capital Medical University, Beijing, China., Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Beijing Institute of Infectious Diseases, Beijing, China; Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Institute of Urology, Capital Medical University, Beijing, China. Electronic address: .